Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 5 vs CARDURA XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
98% bound to sex hormone-binding globulin (SHBG) and albumin.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
None.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 5 vs CARDURA XL, answered by our medical review team.
ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 5 and CARDURA XL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 5 and CARDURA XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.